Ontario’s Darlington nuclear reactor to produce isotope used for medical imaging
TORONTO — Ontario Power Generation plans to modify its Darlington nuclear plant to help produce radioactive isotopes used to diagnose such conditions as cancer and heart disease, the Crown corporation announced Wednesday.
OPG’s subsidiary Canadian Nuclear Partners has teamed up with U.S.-based BWX Technologies to produce the medical isotope technetium-99, a radioactive material widely used in imaging tests to diagnose a variety of diseases.
CANDU reactors at the Darlington plant in Clarington, Ont., east of Toronto would produce molybdenum-99, the “parent” radioisotope that decays into technetium-99.
The site would become the first large-scale commercial station in the world to produce molybdenum-99, said OPG, and would not interfere with the plant’s generation of electricity.


